Holdings Ltd. Dexxon Acquires 11,608 Shares of Urovant Sciences Ltd (UROV) Stock

Urovant Sciences Ltd (NASDAQ:UROV) major shareholder Holdings Ltd. Dexxon purchased 11,608 shares of the business’s stock in a transaction on Friday, May 17th. The stock was acquired at an average price of $7.10 per share, with a total value of $82,416.80. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Shares of NASDAQ UROV opened at $8.33 on Wednesday. Urovant Sciences Ltd has a 52-week low of $4.05 and a 52-week high of $14.49.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. FMR LLC grew its stake in shares of Urovant Sciences by 28.4% during the 1st quarter. FMR LLC now owns 1,710,836 shares of the company’s stock valued at $17,194,000 after buying an additional 378,135 shares during the period. Perceptive Advisors LLC boosted its position in Urovant Sciences by 38.4% during the 1st quarter. Perceptive Advisors LLC now owns 865,359 shares of the company’s stock worth $8,697,000 after purchasing an additional 240,000 shares during the period. BlackRock Inc. purchased a new stake in Urovant Sciences during the 3rd quarter worth $4,574,000. Sphera Funds Management LTD. boosted its position in Urovant Sciences by 30.5% during the 4th quarter. Sphera Funds Management LTD. now owns 214,030 shares of the company’s stock worth $1,410,000 after purchasing an additional 50,000 shares during the period. Finally, Prosight Management LP purchased a new stake in Urovant Sciences during the 1st quarter worth $1,004,000. 22.77% of the stock is owned by institutional investors.

Several research analysts have weighed in on UROV shares. Zacks Investment Research downgraded Urovant Sciences from a “hold” rating to a “sell” rating in a report on Saturday, January 26th. SunTrust Banks started coverage on Urovant Sciences in a report on Friday, March 15th. They issued a “buy” rating and a $24.00 price target for the company. Finally, HC Wainwright assumed coverage on Urovant Sciences in a report on Monday, March 11th. They issued a “buy” rating and a $28.00 price target for the company. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $21.13.

TRADEMARK VIOLATION NOTICE: This piece was first reported by WKRB News and is the property of of WKRB News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://www.wkrb13.com/2019/05/22/holdings-ltd-dexxon-acquires-11608-shares-of-urovant-sciences-ltd-urov-stock.html.

About Urovant Sciences

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.

Recommended Story: Quick Ratio

Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.